Sphera Funds Management’s Krystal Biotech KRYS Stock Holding History

Sphera Funds Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-7,335	Closed	-$1.01M	–	123
2025 Q2	$1.01M	Buy	+7,335	New	+$1.08M	0.24%	88
2022 Q2	–	Sell	-25,310	Closed	-$1.68M	–	68
2022 Q1	$1.68M	Buy	+25,310	New	+$1.58M	0.24%	56
2021 Q1	–	Sell	-101,044	Closed	-$6.06M	–	187
2020 Q4	$6.06M	Sell	101,044 -83,529	-45%	-$4.17M	0.54%	58
2020 Q3	$7.95M	Buy	184,573 +40,000	+28%	+$1.74M	0.78%	36
2020 Q2	$5.99M	Buy	+144,573	New	+$6.96M	0.56%	45
2020 Q1	–	Sell	-86,280	Closed	-$4.78M	–	91
2019 Q4	$4.78M	Sell	86,280 -31,345	-27%	-$1.54M	0.39%	56
2019 Q3	$4.08M	Hold	117,625	–	–	0.63%	49
2019 Q2	$4.74M	Sell	117,625 -64,000	-35%	-$2.09M	0.65%	46
2019 Q1	$5.97M	Buy	181,625 +7,000	+4%	+$165K	0.55%	40
2018 Q4	$3.63M	Buy	+174,625	New	+$3.66M	0.41%	56

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sphera Funds Management's KRYS Position: Q3 2025 in Review

Sphera Funds Management sold out of Krystal Biotech (KRYS) in Q3 2025, closing a stake of 7,335 shares — an estimated $1.01M sold.

Sphera Funds Management first reported a position in KRYS in Q4 2018 and held it in 10 quarters. The position peaked at $7.95M in Q3 2020. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

Sphera Funds Management reported no remaining Krystal Biotech position as of Q3 2025 after selling out during the quarter.
Sphera Funds Management sold 7,335 Krystal Biotech shares in Q3 2025, an estimated $1.01M.
Sphera Funds Management first reported a position in Krystal Biotech in Q4 2018 and held it in 10 quarters.
Sphera Funds Management's Krystal Biotech position peaked at $7.95M in Q3 2020.
284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.